High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma

Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis

(2018) Kevin Phan et al.   World Neurosurgery

Mutant IDH1 and seizures in patients with glioma

(2017) Hao Chen et al.   NEUROLOGY

Comparative analysis of antibodies to xCT (Slc7a11): Forewarned is forearmed

(2015) Joeri Van Liefferinge et al.   JOURNAL OF COMPARATIVE NEUROLOGY

SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma

(2015) Stephanie M. Robert et al.   Science Translational Medicine

ILAE Official Report: A practical clinical definition of epilepsy

(2014) Robert S. Fisher et al.   EPILEPSIA

Cortical GABAergic excitation contributes to epileptic activities around human glioma

(2014) J. Pallud et al.   Science Translational Medicine

Tumoral epileptogenicity: How does it happen?

(2013) Johan Pallud et al.   EPILEPSIA

Glutamate is associated with a higher risk of seizures in patients with gliomas

(2012) T. I. Yuen et al.   NEUROLOGY

Glutamate release by primary brain tumors induces epileptic activity

(2011) Susan C Buckingham et al.   NATURE MEDICINE

Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

(2009) Patrick Kwan et al.   EPILEPSIA

Recommendation for a definition of acute symptomatic seizure

(2009) Ettore Beghi et al.   EPILEPSIA